ACELYRINSLRN
About: Acelyrin Inc is a late-stage clinical biopharmaceutical company. It is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of of transformative medicines.
Employees: 130
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
450% more call options, than puts
Call options by funds: $22K | Put options by funds: $4K
29% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 14
10% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 40
2% more funds holding
Funds holding: 122 [Q3] → 124 (+2) [Q4]
0.62% less ownership
Funds ownership: 88.26% [Q3] → 87.64% (-0.62%) [Q4]
33% less funds holding in top 10
Funds holding in top 10: 3 [Q3] → 2 (-1) [Q4]
36% less capital invested
Capital invested by funds: $434M [Q3] → $276M (-$158M) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Citigroup Samantha Semenkow 17% 1-year accuracy 2 / 12 met price target | 12%upside $3 | Neutral Maintained | 7 Jan 2025 |
HC Wainwright & Co. Emily Bodnar 18% 1-year accuracy 28 / 157 met price target | 123%upside $6 | Neutral Maintained | 7 Jan 2025 |
Financial journalist opinion
Based on 4 articles about SLRN published over the past 30 days









